At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed locally advanced or metastatic cervical cancer
- ✓Progression or intolerance to at least one prior therapy line
- ✓Measurable disease by RECIST 1.1
- ✓Archival or newly obtained tumor tissue sample provided
- ✕Prior anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy
- ✕Prior systemic anti-cancer therapy within 4 weeks
- ✕Prior radiotherapy within 2 weeks (1-week washout allowed for palliative)
- ✕Live vaccine within 30 days prior to first dose
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Combination Therapy of Pembrolizumab and Lenvatinib in Patients With Locally Advanced or Metastatic Cervical Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab and Lenvatinib for Cervical Cancer and Metastatic Cervical Cancer. Currently recruiting, targeting 35 participants across 4 sites.
Detailed Summary
This is a phase II trial of combination therapy of pembrolizumab and lenvatinib in patients with locally advanced or metastatic cervical cancer that had failed first line of therapy. The hypothesis is the combination of lenvatinib and pembrolizumab will overcome vascular endothelial growth factor (VEGF)-mediated immunosuppression to enhance the response of patients with locally advanced or metastatic cervical cancer.
Study Details
Timeline
Interventions
200mg, every 3 weeks, IV infusion
20 mg (2 capsules x10mg), daily, orally